AMB 102
Alternative Names: AMB-102Latest Information Update: 03 Mar 2023
At a glance
- Originator AmMax Bio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 03 Mar 2023 AMB 102 is available for licensing as of 11 Jan 2023. https://www.ammaxbio.com/partnering (AmMax Bio pipeline, January 2023)
- 11 Jan 2023 Early research in Solid tumours in USA (Parenteral) (AmMax Bio pipeline, January 2023)